CrossRef Anti-diabetic Drugs and Cancer: Integrated Mechanisms of Tumor Suppression and Clinical Translation Mahya Asadalizadeh, Mohammad Kazem Molavi Rahbar, Tabassom Mahmoudie, Mahshid Abbasi, Mitra Akbari, Davoud Shakiba, Aida Mohammadiun Shabestari, Meysam Ebrahimifar Indian Journal of Clinical Biochemistry.2026;[Epub] CrossRef Glucagon-like Peptide-1 receptor agonists are not associated with increased risk of pancreatic cancer: A systematic review and meta-analysis Gaetano Lauri, Paolo Giorgio Arcidiacono, Antonio Facciorusso, Gabriele Capurso, Matteo Tacelli Pancreatology.2026;[Epub] CrossRef GLP-1 Receptor Agonists: Therapeutic Potential and Emerging Concerns Klaudia Nowak, Krzysztof upina, Aleksandra Kalisz, ucja Ilkiewicz, Jakub Janczura Current Pharmacology Reports.2026;[Epub] CrossRef Optimizing glycemic control in oncology patients with diabetes mellitus S
It is not approved for use with certain medications or in individuals with specific health conditions affecting blood pressure or heart health
you are potentially multiplying their effectiveness
Tablets and injections get there by different routes
